Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape
Megan Dutton, Paul Schwenn, Jules S Mitchell, Per Hoffmann, Neil W. Bailey, Paul B. Fitzgerald, Jim Lagopoulos, Adem T. Can
Australian & New Zealand Journal of Psychiatry December 17, 2025 DOI: 10.1177/00048674251398677 (opens in new tab)
The journal has published a correction to this paper. Read the correction (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin-assisted therapy |
| Topics | Psilocybin |
| Keywords | Mental health Context archaeology Novelty Accreditation Fidelity Multidisciplinary approach Ethical issues Engineering ethics Psychotherapist |
| Citations | 1 |
| Key findings | Australia's reclassification of psilocybin for treatment-resistant depression is a policy shift, but implementation is hindered by limited prescriber access, lack of approved products, absent training pathways, and cost barriers, requiring structural reforms for safe and equitable deployment. |
Abstract
Australia’s reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities surrounding the provision of psilocybin-assisted therapy in clinical practice. Key issues include limited prescriber access, absence of Australian Register of Therapeutic Goods-listed products, lack of standardised training pathways and significant cost barriers. Ethical considerations such as informed consent, cultural safety and therapeutic fidelity are also discussed, particularly in the context of trauma-informed care. This article proposes a series of structural recommendations to support safe and equitable deployment, including national training accreditation and fidelity monitoring tools. In addition, to maximise the efficacy of psilocybin-assisted therapy, we recommend that research explores the potential of neurobiologically informed stratification models to assist with treatment recommendations. These recommendations aim to enhance clinical integrity through evidence-based patient selection, improved safety, and to ensure that emerging psychedelic treatments are integrated responsibly within Australia’s mental health system. By addressing these foundational gaps, Australia can move beyond regulatory novelty ensuring the therapeutic potential of these products is realised in a manner which is scientifically sound and upholds the integrity of psychiatric practice.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cites 28
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psychedelics and the essential importance of context. Journal of Psychopharmacology February 15, 2018
- The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science December 10, 2020
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
and 23 more in the library